Baseline characteristics of men and women. Mean (SD) reported unless otherwise specified.
| Characteristics | Men, n = 1142 (21%) | Women, n = 4393 (79%) | p | ||
|---|---|---|---|---|---|
| Values | N | Values | N | ||
| Age at first visit, yrs | 52.0 (14.9) | 1139 | 46.9 (13.9) | 4371 | < 0.001 |
| BMI, kg/m2 | 27.1 (4.8) | 730 | 27.0 (6.6) | 2500 | 0.647 |
| RF-positive, % | 70.6 | 1104 | 75.5 | 4270 | 0.001 |
| ACPA-positive, % | 66.3 | 656 | 70.8 | 2363 | < 0.001 |
| Smoking, % | 900 | 3832 | < 0.001 | ||
| Never | 62.3 | 88.5 | |||
| Previous smoker | 14.2 | 5.2 | |||
| Current smoker | 23.0 | 6.3 | |||
| Symptom duration at diagnosis, mos, median (IQR) | 10.3 (3.9–23.9) | 1142 | 12.3 (5.9–34.8) | 4393 | < 0.001 |
| Time to treatment initiation from diagnosis, days | 4.3 (14.8) | 1142 | 3.8 (14.0) | 4393 | 0.009 |
| HAQ, 0–3 | 0.96 (0.69) | 897 | 1.1 (0.68) | 3668 | < 0.001 |
| DAS | 3.5 (1.1) | 753 | 3.7 (1.0) | 2689 | < 0.001 |
| DAS28 | 5.5 (1.4) | 817 | 5.8 (1.4) | 2933 | < 0.001 |
| ESR, mm/h | 46.2 (32.2) | 1017 | 57.4 (33.7) | 3809 | < 0.001 |
| CRP, mg/l, median (IQR) | 24 (11–50) | 869 | 21 (9–45) | 3391 | < 0.001 |
| VAS patient global, 0–100 | 53.5 (23.0) | 896 | 55.0 (22.0) | 3295 | 0.091 |
| Ritchie articular index, 0–78 | 8.6 (6.4) | 1061 | 10.2 (6.6) | 4075 | < 0.001 |
| SJC, 0–44 | 7.2 (7.4) | 1062 | 6.5 (6.5) | 4079 | 0.027 |
| TJC 28, 0–28 | 10.9 (8.7) | 1129 | 12.6 (9.3) | 4347 | < 0.001 |
| SJC 28, 0–28 | 6.4 (6.2) | 1133 | 5.8 (5.5) | 4368 | 0.021 |
BMI: body mass index; RF: rheumatoid factor; ACPA: anticitrullinated protein antibodies; IQR: interquartile range; HAQ: Health Assessment Questionnaire; DAS: Disease Activity Score; DAS28: 28-joint DAS; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; VAS: visual analog scale; SJC: swollen joint count; SJC28: 28-joint SJC; TJC28: 28-joint tender joint count.